LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced on April 2, 2026, that it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, detailing what the company describes as a transformational year. The filing highlights leadership changes, clinical progress for its lead compound LB-100, and strategic expansion through the acquisition of Liora Technologies Europe Ltd., a developer of advanced proton therapy systems.
The company advanced development of LB-100, a first-in-class PP2A inhibitor, by expanding clinical trials with additional sites and increasing enrollment. LB-100 is being evaluated in proof-of-concept trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. According to the company, published preclinical data suggest LB-100 has the potential to enhance chemotherapies and immunotherapies, improving outcomes for cancer patients. The compound is part of a pioneering effort in a new field of cancer biology called activation lethality.
In addition to clinical advances, LIXTE completed the acquisition of Liora Technologies Europe Ltd., a wholly owned subsidiary focused on electronically controlled proton therapy systems. Liora's flagship LiGHT System is believed to offer significant advantages over current technologies for treating tumors with proton therapy. This acquisition broadens LIXTE's oncology platform beyond small-molecule inhibitors into advanced radiation therapy.
To support these initiatives, LIXTE raised more than $11 million during 2025, strengthening its balance sheet and providing capital for continued growth. The company also underwent leadership changes, though the press release does not specify details. The Form 10-K provides a comprehensive overview of these developments and the company's financial position.
Investors can access the full press release at https://ibn.fm/LP6QH. Additional information about LIXTE and its pipeline is available at www.lixte.com.
The company cautions that forward-looking statements in the filing involve risks and uncertainties, as detailed in the Risk Factors section of the Form 10-K and other SEC filings. These factors could cause actual results to differ materially from expectations.
